
Nirsevimab
CAS No. 1989556-22-0
Nirsevimab( —— )
Catalog No. M36818 CAS No. 1989556-22-0
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 755 | Get Quote |
![]() ![]() |
5MG | 1264 | Get Quote |
![]() ![]() |
10MG | 2014 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameNirsevimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.
-
DescriptionNirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorRSV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1989556-22-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Griffin MP, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. ?
molnova catalog



related products
-
Palivizumab
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
-
HJC0152
A potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo.
-
Pimozide
Pimozide is an antipsychotic agent that acts as an antagonist of the D2, D3, and D4 receptors and the 5-HT7 receptor.